Novartis AG: Number of Employees 2010-2024 | NVS
Interactive chart of Novartis AG (NVS) annual worldwide employee count from 2010 to 2024.
- Novartis AG total number of employees in 2024 was 75,883, a 0.23% decline from 2023.
- Novartis AG total number of employees in 2023 was 76,057, a 25.22% decline from 2022.
- Novartis AG total number of employees in 2022 was 101,703, a 2.51% decline from 2021.
- Novartis AG total number of employees in 2021 was 104,323, a 1.39% decline from 2020.
| Novartis AG Annual Employee Count |
| 2024 |
75,883 |
| 2023 |
76,057 |
| 2022 |
101,703 |
| 2021 |
104,323 |
| 2020 |
105,794 |
| 2019 |
103,914 |
| 2018 |
125,161 |
| 2017 |
121,597 |
| 2016 |
123,000 |
| 2015 |
118,700 |
| 2014 |
133,413 |
| 2013 |
135,696 |
| 2012 |
127,724 |
| 2011 |
123,686 |
| 2010 |
119,418 |
| 2009 |
99,834 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$223.511B |
$50.317B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
